This page shows the latest Tecfidra news and features for those working in and with pharma, biotech and healthcare.
8%, 15.4% and 14.6% for Vumerity 40.6%, 22.3% and 20.7% for Tecfidra).
Company banking on pipeline readouts and Tecfidra defence. Biogen has exceeded expectations in overall Q2 revenues from its multiple sclerosis franchise and biosimilars, but worse than expected performance from its key
Much riding on blockbuster's successor
While this pipeline will take time to mature, and Tecfidra facing a patent challenge in the US, the strong performance of Spinraza and its biosimilar franchise helped Biogen keep moving forward. ... Biogen and partner Alkermes are also awaiting an FDA
Improved GI tolerability is major selling point
More from news
Approximately 3 fully matching, plus 2 partially matching documents found.
We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...